Sector News

GSK to divest Rabipur, Encepur to Bavarian Nordic

October 22, 2019
Life sciences

GlaxoSmithKline (GSK) has announced plans to divest its travel vaccines Rabipur and Encepur to Bavarian Nordic.

The two vaccines are for rabies prevention and tick-borne encephalitis respectively, both acquired from Novartis in 2015 as part of the acquisition of its vaccines business.

Rabipur is a well-established life-saving vaccine with 30 years of market experience supported by extensive clinical and safety evidence and World Health Organisation (WHO) pre-qualification.

Encepur is indicated for active immunisation of high-risk populations against tick-borne encephalitis, with a unique dosing flexibility supported by proven efficacy and long-term persistence data.

GSK says that the move supports the company’s strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business.

The agreement will “enable us to commit greater resources to our key growth assets and to our R&D pipeline, while also ensuring the continued supply of these important and successful vaccines,” says Roger Connor, president, Global Vaccines at GSK.

The pharma giant will receive an upfront payment of approximately £259 million as well as milestone payments and additional proceeds from the sale of inventory over the course, totaling a potential £821 million (955 million euros).

To ensure supply continuity, the company has announced that both vaccines will continue to be manufactured primarily at GSK’s Marburg site in Germany until full production is transferred to Bavarian Nordic.

The transaction is expected to close by the end of 2019 and is conditional upon anti-trust approval as well as approval of Bavarian Nordic’s rights issue by its shareholders

By Anna Smith

Source: Pharma Times

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach